+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

HER-2 Negative Breast Cancer Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

  • PDF Icon


  • 120 Pages
  • January 2022
  • Region: Global
  • Mordor Intelligence
  • ID: 4997425

The human epidermal growth factor receptor 2 (HER-2) negative breast cancer refers to the cancerous cells in the breast which do not contain high levels of protein HER-2. The major requirement in the present decade is to improve upon the maximising the symptom control and extending survival. In all types of breast cancers, one of the major drawback is that despite the advancements in the treatment of early stage of breast cancers, the recurrence of the disease among the patients is quite common. While, HER-2 positive is highly prevalent across all geographies, the presence of HER-2 negative is also steadily growing and clinical advancement as well as research development activities in this direction is expected to grow better over the forecast period. The high cost of treatment and availability of alternative treatments are expected to restrict the growth of this market.

Key Market Trends

Treatment via Hormonal therapy is Expected to be the Major Contributor to the Market

  • There are several drugs approved in the market which can block the hormones or lower their levels in the body, which helps in treatment of HER-2 negative breast cancer. Some of the well-established drugs include tamoxifen, fulvestrant, goserelin, olaparib, and others.
  • Some of the companies advancing their drugs development and R&D activities in this sub-segment of the market include AstraZeneca, Biomarin, Abbvie, Merck and Co. Inc., and Tesaro, with their products in the late the stage of clinical development.
  • One of the challenges among the manufacturers is the occurrence of resistance is common problem in hormonal therapy. Therefore, combination therapy with hormonal therapy to prevent or overcome the hormone resistance is highly considered and are into development.

North America is Expected to Hold a Significant Share in the Market with Similar Trend in the Forecast Period

North America expected to hold a major market share in the global HER-2 negative breast cancer market owing to better healthcare infrastructure, and growing number of foundations and independent venture groups supporting the biopharmaceutical manufacturers. The presence of major manufacturers across the different states, getting funding from different venture partners drives the market related to HER-2 negative breast cancer. As per the American cancer Society, 2017-2018, the negative HER-2 cancers are twice as common in the black women as compared to white women in the United States, also more common in the in pre-menopausal women and those with a BRCA1 gene mutation. The challenges associated within such population is early diagnosis and right treatment procedure to the identified set of patient population with the HER-2 negative breast cancers. The availability of good government support along with better disposable income option among all populations as well as good percentage of medical tourism across the North America region, fuels the market growth.

Competitive Landscape

The major focus among the companies is to develop combination therapies which shall overcome the resistance of existing drug therapies in the market thus boosting the targeted disease treatment. This is done via collaboration, and partnerships among the market players. Some of the major companies in this segment include AstraZeneca, Eli Lilly and Company, Novartis AG, Pfizer, GSK, and others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.

Table of Contents

1.1 Study Assumptions
1.2 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Burden of Breast Cancers
4.2.2 Medical Advancements by Breast Cancers Treatment
4.3 Market Restraints
4.3.1 High Cost of Treatment
4.3.2 Less Awareness Regarding HER-2 Negative Breast Cancer
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1 By Type of Treatment
5.1.1 Chemotherapy
5.1.2 Radiation
5.1.3 Hormonal Therapy
5.1.4 Others
5.2 Geography
5.2.1 North America United States Canada Mexico
5.2.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.2.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.2.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.2.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 AstraZeneca PLC
6.1.2 Celgene Corporation (Bristol Myers Squibb Company)
6.1.3 Eli Lilly and Company
6.1.4 GlasxoSmithKline
6.1.5 Merck & Co., Inc.
6.1.6 Novartis AG
6.1.7 Pfizer

Companies Mentioned

A selection of companies mentioned in this report includes:

  • AstraZeneca PLC
  • Celgene Corporation (Bristol Myers Squibb Company)
  • Eli Lilly and Company
  • GlasxoSmithKline
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer